A recovering IPO market, surging mergers and acquisitions fuel more biotech venture deals.

One of the largest Japan focused biotech funds to date SAN FRANCISCO & TOKYO--(BUSINESS WIRE)--AN Venture Partners (ANV), a global biotech venture capital firm, today announced the final close of its ...

The young venture firm, which has bet heavily on tech and biotech’s convergence, has now invested in 35 companies and ...

China’s nascent challenge has U.S. biotech startups hustling to emulate China’s efficiency and speed in drug development.

Excellergy has emerged with $70 million and an investigative drug class in its portfolio, part of its ambitious mission to achieve complete therapeutic control of several allergic conditions by ...

Though funding totals represented the highest first-half sum since the start of 2022, industry watchers are concerned that small startups are being left behind.

Now in its sixth year, this STAT Report has become the go-to guide for understanding who’s truly delivering in the high-stakes world of biotech investing and why. In this report preview, get your ...

Venture financing for UK biotechs reached a five-year high in the second quarter of the year, with more than £2 billion ...

Earlier this month, the Trump administration directed the National Institutes of Health (NIH) to impose limits on specific types of funding it provides to research institutions. Although a federal ...

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The ...

A San Diego biotech has set out to solve the formula for best-in-class antibody-drug conjugates, raising $120 million with support from Big Pharma Merck & Co. to fuel its efforts. Solve Therapeutics’ ...